Arcellx, Inc.

    Arcellx, Inc.

    NNASDAQ:ACLX
    115.07
    USD
    0.00
    (0.00%)
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    2025 Y
    TTM
    Revenue per Share
    - -
    - -
    - -
    - -
    2.3
    2.02
    - -
    0.4
    Basic EPS, GAAP
    -1.67
    -1.47
    -1.94
    -5.19
    -1.47
    -2
    - -
    -4.09
    Free Cash Flow per Basic Share
    -2.1
    -1.36
    -1.79
    -2.79
    3.87
    -1.81
    - -
    -3.79
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    -3.06
    -2.99
    -3.88
    -8.77
    -8.1
    -9.27
    - -
    -12.95
    Tangible Book Value per Share
    -3.04
    -2.93
    -3.62
    5.64
    10.1
    8.49
    - -
    7.18
    Basic Weighted Avg Shares
    11
    22
    34
    36
    48
    54
    - -
    56
    Sales/Revenue/Turnover
    - -
    - -
    - -
    - -
    110
    108
    22
    22
    Operating Margin (%)
    - -
    - -
    - -
    - -
    -81.47
    -127.46
    -1,135.61
    -1,135.61
    Depreciation Expense
    - -
    1
    1
    1
    2
    5
    7
    7
    Net Income, GAAP
    -18
    -32
    -65
    -189
    -71
    -107
    -229
    -229
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    - -
    - -
    - -
    - -
    -64.08
    -99.46
    -1,027.25
    -1,027.25
    Working Capital
    35
    44
    98
    210
    598
    474
    358
    358
    LT Debt
    - -
    - -
    - -
    52
    51
    47
    44
    44
    Total Equity
    -33
    -64
    -122
    205
    485
    455
    402
    402
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Jun'25
    Sep'25
    Dec'25
    ST Debt
    7
    7
    8
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    45
    44
    44
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    55
    58
    58
    Market Capitalization
    3,628
    4,599
    3,653

    Working Capital

    USD

    •

    in mil. unless spec.
    Jun'25
    Sep'25
    Dec'25
    Total Current Assets
    464
    472
    462
    Cash, Cash Equivalents & STI
    453
    461
    450
    Accounts Receivable, Net
    - -
    - -
    - -
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    122
    118
    104
    Payables & Accruals
    40
    34
    22
    ST Debt
    7
    7
    8
    Deferred Revenue
    59
    60
    56

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    -11.8%
    -11.53%
    Free Cash Flow
    - -
    -28.71%
    119.38%
    Net Income, GAAP
    - -
    79.09%
    113.26%
    Sales/Revenue/Turnover
    - -
    - -
    -79.35%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    18
    14
    15
    63
    110
    2024
    39
    27
    26
    15
    108
    2025
    8
    8
    5
    2
    22

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    -0.58
    -0.5
    -0.81
    - -
    -1.47
    2024
    -0.14
    -0.51
    -0.48
    - -
    -2
    2025
    -1.13
    -0.94
    -0.99
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -

    Company Description

    Address
    Similar Companies
    Business

    Company News

    • Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

    • Are Medical Stocks Lagging Arcellx (ACLX) This Year?

    • Arcellx, Inc. (NASDAQ:ACLX) Given Consensus Recommendation of “Hold” by Analysts

    • Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer

    • Banque Pictet & Cie SA Acquires Shares of 5,109 Arcellx, Inc. $ACLX

    • Gilead Extends Tender Offer to Acquire Arcellx

    • Are ACLX, MASI, FONR Obtaining Fair Deals for their Shareholders?

    • Halper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their Shareholders

    • This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal

    • Are MASI, ACLX, GLDD Obtaining Fair Deals for their Shareholders?

    • Bamco Inc. NY Has $45.17 Million Stake in Arcellx, Inc. $ACLX

    • Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

    • Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise?

    • Are ACLX, DBRG, AVO, CVGW Obtaining Fair Deals for their Shareholders?

    • The M&A Class Action Firm Encourages $hareholders to Contact Monteverde Concerning the Merger—ACLX, VRE, EHAB, and CECO

    • Arcellx, Inc. (NASDAQ:ACLX) Receives Average Rating of “Hold” from Analysts

    • Halper Sadeh LLC is Investigating Whether ACLX, VRE, EHAB are Obtaining Fair Deals for their Shareholders

    • Top 2 Health Care Stocks That May Crash This Quarter

    • Baron Health Care Fund Q4 2025 Contributors And Detractors

    • Arcellx President Sells $10M Worth of Shares After Acquisition Announcement